Amidst the towering legal battles, Johnson & Johnson (J&J) finds itself threading a strategic path, settling disputes with numerous law firms regarding allegations that its talc products contributed to cancer. Revealing this development, Erik Haas, J&J’s global vice president for litigation, shared insights during an investor call, outlining a roadmap aimed at expediting a consensual prepackaged bankruptcy resolution.
These settlements, although veiled in uncertainty regarding their finalization, target cases involving mesothelioma, a cancer strain associated with asbestos. The company, however, remains tight-lipped about specific financial details and the number of individuals covered by these settlements.
Haas affirmed that J&J has successfully wrapped up almost all cases slated for trial in 2023, significantly reducing trial engagements in 2024. Importantly, these resolutions do not compel the company to register additional charges against its earnings.
Earlier reports from Bloomberg hinted at settlements impacting approximately 100 individuals, shedding light on the scale of J&J’s efforts to tackle over 50,000 talc-related lawsuits, primarily filed by women attributing ovarian cancer to the company’s products. Notably, a fraction of these cases involves individuals afflicted with mesothelioma. J&J has consistently asserted the safety of its talc products, adamantly denying any asbestos content.
The legal landscape surrounding J&J’s talc predicament had been momentarily suspended as the company sought refuge in the bankruptcy court. With recent settlements, these lawsuits have now regained momentum.
Trials in the talc cases have yielded mixed outcomes, with significant victories for plaintiffs, such as a $2.1 billion judgment in 2021 for 22 women with ovarian cancer. Conversely, a New Jersey appeals court nullified a $223.7 million verdict in October, deeming the testimony of plaintiffs’ expert witnesses unreliable.
J&J, reacting to the surge in lawsuits and what it terms “misinformation” about talc product safety, opted to cease the sale of talc-based baby powder in favor of cornstarch-based alternatives.
As the legal saga unfolds, Johnson & Johnson treads a precarious path, leveraging strategic settlements while contemplating the prospect of bankruptcy to navigate through the complex web of talc-related litigations.
